The award provides intellectual property protection for Biocept's Primer-Switch technology that is useful for ctDNA analysis using real-time PCR and associated analysis methods, including next-generation sequencing (NGS).
"The issuance of this patent expands Biocept's intellectual property protection for rare mutation detection," said Lyle Arnold, chief scientific officer, in a statement.
"The Primer-Switch is a method for the detection of rare genetic events and is an addition to our Switch-Blocker technology, which is routinely used with our ctDNA Target Selector assays,” he added.
READ: Biocept unveils second contract for its assay services with California independent physician association
Arnold noted that this is the first issued patent for the Primer-Switch technology, which the San Diego-based company believes will achieve eventual worldwide patent protection.
“It provides another tool in Biocept's toolkit of methods to inform on biomarkers to aid physician decision-making in the treatment of cancer patients," he added.
The recently issued Australian patent is another method for specifically enriching patient specimens for oncogene mutations of interest, the company explained.
The Primer-Switch technology is used as part of PCR reactions, which are core to the most commonly used method of amplification in diagnostic assays. Primer-Switch methodology has the potential to find wide use in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplifications are desired.
"The expansion of our intellectual property continues the global validation of our technology and further positions Biocept as a provider of cutting-edge approaches for the detection of rare genetic events using blood and other fluids," said CEO Michael Nall.
"We continue to develop innovative products and technologies such as Primer-Switch to stay ahead of the curve in liquid biopsy technology."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham